Role of preoperative intravenous iron therapy to correct anemia before major surgery: a systematic review and meta-analysis

Abdelsalam M. Elhenawy 1,2*, Steven R. Meyer 1, Sean M. Bagshaw 3, Roderick G. MacArthur 1 and Linda J. Carroll 4

Abstract

Background: Preoperative anemia is a common comorbidity that often necessitates allogeneic blood transfusion (ABT). As there is a risk associated with blood transfusions, preoperative intravenous iron (IV) has been proposed to increase the hemoglobin to reduce perioperative transfusion; however, randomized controlled trials (RCT) investigating this efficacy for IV iron are small, limited, and inconclusive. Consequently, a meta-analysis that pools these studies may provide new and clinically useful information.

Methods/design: Databases of MEDLINE, EMBASE, EBM Reviews; Cochrane-controlled trial registry; Scopus; registries of health technology assessment and clinical trials; Web of Science; ProQuest Dissertations and Theses; Clinicaltrials.gov; and Conference Proceedings Citation Index-Science (CPCI-S) were searched. Also, we screened all the retrieved reference lists.

Selection criteria: Titles and abstracts were screened for relevance (i.e., relevant, irrelevant, or potentially relevant). Then, we screened full texts of those citations identified as potentially applicable.

Results: Our search found 3195 citations and ten RCTs (1039 participants) that met our inclusion criteria. Preoperative IV iron supplementation significantly decreases ABT by 16% (risk ratio (RR): 0.84, 95% confidence interval [CI]: 0.71, 0.99, p = 0.04). In addition, preoperatively, hemoglobin levels increased after receiving IV iron (mean difference [MD] between the study groups: 7.15 g/L, 95% CI: 2.26, 12.04 g/L, p = 0.004) and at follow-up > 4 weeks postoperatively (MD: 6.46 g/L, 95% CI: 3.10, 9.81, p = 0.0002). Iron injection was not associated with increased incidence of non-serious or serious adverse effects across groups (RR: 1.13, 95% CI: 0.78, 1.65, p = 0.52) and (RR: 0.96, 95% CI: 0.44, 2.10, p = 0.92) respectively.

(Continued on next page)
Background
Preoperative anemia remains the most common hematological deficit affecting the patients undergoing major surgery. It is an independent risk factor for perioperative allogeneic blood transfusion (ABT), as revealed in a meta-analysis of 949,445 patients [1] and associated with increased postoperative morbidity and mortality [2–5]. However, the evidence to support the treatment of anemia with transfusion in a perioperative setting is still lacking and requires further research. Recently, two large transfusion trigger meta-analyses reported different results. The first study reported similar mortality rates when a restrictive or liberal transfusion strategy was applied [6]. Unfortunately, this study investigated only the mortality outcome without reporting data on the morbidity occurrence post-transfusion, and their patients’ populations are heterogeneous being a mixture of medical and surgical settings [6]. The second meta-analysis showed that the restrictive transfusion strategy was associated with less mortality and morbidity in the critical care arm of the study [7]. Interestingly, in the perioperative population, the restrictive transfusion strategy with transfusion triggers of 7–7.5 g/dL may increase the risk of mortality. However, the investigators considered this finding of less robust evidence due to being insufficiently accumulated sample size compared with the critical care population recommending further research [7].

Furthermore, several literatures reported that blood transfusion is associated with adverse outcomes perioperatively [8–10]. Furthermore, data obtained from two large multicenter databases of 23,348 patients [11], and 227,425 patients [12] demonstrated that not only severe but also moderate/mild preoperative anemia is an independent risk factor for postoperative morbidity and 30-day mortality. These findings would suggest that approaches to reduce avoidable ABT might be associated with improved postoperative outcomes.

Although it is correctable [4], iron-deficiency anemia (IDA) remains the most frequent category of anemia that develops in patients undergoing major surgery [13, 14] due to inadequate iron intake and substantial blood loss perioperatively [15]. Oral iron supplementation requires a long time to replenish the exhausted iron stores and is associated with intolerability in about 70% of patients [16]. In contrast, intravenous (IV) iron supplementation allows for a large quantity of iron to be administered over a few doses and has excellent availability for erythropoiesis [17], to increase the hemoglobin (Hb) concentration significantly in nonsurgical recent studies; a review [18], a randomized controlled trial (RCT) [19], and several meta-analyses [20–22].

Intravenous iron therapy for preoperative anemia has been tested in some RCTs. However, to date, the evidence to support its safety and efficacy is unclear. Due to the paucity of trials, most of which are of small sample size and have negative outcomes, which may be a result of being underpowered, there is insufficient evidence to support the use of IV iron to decrease ABT. A meta-analytic approach that pools these studies would aid in addressing the limitations of trial size, which would increase the power to observe statistically significant differences and may provide new and clinically useful evidence. This meta-analysis will investigate (a) the ability of parenteral iron administration to reduce ABT requirement by improving preoperative Hb concentrations, and (b) the safety of parenteral iron in terms of mortality, morbidity, and adverse events (AEs) compared with placebo/oral iron as the standard of care.

Patients and methods
Protocol and registration
Our study protocol has been published [23] and registered with the International Prospective Register of Systematic Reviews (PROSPERO), systematic review registration number: PROSPERO CRD42015016771) on February 16, 2015. Initially, following our published inclusion/exclusion criteria [23], we found only two eligible trials of small sample size. Consequently, to recruit more trials, we had to modify our inclusion/exclusion criteria (Additional File 1 A) and make an update on the PROSPERO website on April 27, 2017. The current study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [24] (Additional file 1 B).

Eligibility criteria
To be eligible, a study had to be a randomized or quasi-randomized controlled clinical trial investigating adult
surgical participants in which the intervention drug was IV iron as monotherapy, initiated/completed preoperatively. Being comprehensive, we did not apply any publication date/status or language restrictions.

**Search strategy**

With the help of a health sciences librarian, using our search strategy (Additional File 1 C), the following databases were searched: MEDLINE, EMBASE; EBM Reviews; the Cochrane-controlled trial registry in the Cochrane Library; Scopus; registries of health technology assessment and clinical trials; and Web of Science. In addition, we searched the ProQuest Dissertations and Theses database; the ClinicalTrials.gov website (National Institute of Health) for completed but unpublished studies; and Conference Proceedings Citation Index (CPCI)-Science since 1990.

The search was started from the earliest retrievable date of each database to February 2019, supplemented by a manual search of reference lists of all retrieved trials, previous reviews of related areas, and Google engine. We ran an updated search on 26 October 2020, which came up with a pilot study in cardiac surgery [25], and a trial in abdominal surgery [26], and we decided to include both in our update.

**Study screening and data extraction**

Authors AE and SM conducted all study screening. Then, they reviewed the titles, abstracts, and reference lists of all included publications to retrieve potentially relevant studies. Full text of retrieved studies was subjected to a second phase of screening for eligibility as defined by the modified inclusion/exclusion criteria and study design for methodological quality. In cases of study eligibility disagreement occurred, a consensus was accomplished through discussion. The same two authors (AE and SM) reviewed the relevant studies and extracted the relevant data using a structured form as per our protocol [23].

In our published protocols, the secondary outcomes were the number of units of blood or blood products transfused perioperatively, all-cause mortality, transfusion-related acute lung injury, neurologic complications, adverse events, postoperative infections, cardiopulmonary complications, intensive care unit (ICU) admission/re-admission, length of hospital stay, acute kidney injury, development of antibodies against platelets or white blood cells, post-transfusion purpura, graft vs. host disease, infection, immunomodulation, and iron overload. However, due to the absence/insufficient data from the primary trials, we were not able to achieve meta-analyses for some of the secondary outcomes.

On the other hand, other secondary outcomes that were not planned in our protocol as the health-related quality of life (HRQoL) measure as indicators for the quality of recovery post-surgery, the IDA parameters including reticulocyte percentage, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were reported in this meta-analysis since we found such data published in the included trials.

**Assessment of the risk of bias**

The Cochrane Collaboration’s tool (Additional File 1 D) was used [27] to evaluate the studies sources of bias.

**Data synthesis and analysis**

For primary outcomes, proportions of study participants who received an ABT was analyzed as risk ratios (RR) with their 95% confidence intervals (CIs); in contrast, the hematopoietic response was analyzed as the mean difference (MD) with their 95% CI for the Hb concentration change with its statistical significance between groups. Safety outcomes, including mortality, infection, and treatment-related AEs, were analyzed as RR with their 95% CIs.

Where standard deviation (SD) was not reported, the trial’s authors were contacted in an effort to get the primary data to compute it. In the absence of SD information, SDs were estimated from 95% CIs, z-statistics, and p values or imputed using the largest reported SD from other trials [28].

The Cochran’s Q test was used to calculate the statistical heterogeneity among studies. An I² value ≥ 40% suggests substantial statistical heterogeneity, and a random-effects model (DerSimonian and Laird technique) [29] was appropriate. With absent or low heterogeneity (I² value < 40%) [30], the fixed-effects model (Mantel-Haenszel technique) was appropriate, with a random-effects model as a sensitivity analysis. The Z test was used to test the overall effect. We conducted a sensitivity analysis on our primary efficacy outcomes and safety outcome by excluding trials with a high risk of bias for one or more key domains [30]. In the analyses, to avoid moving the pooled estimate of IV iron treatment effect closer to null, initially, all trials reporting zero-event data for both trial arms were excluded from the analysis. Then, the analysis was repeated, including these trials to identify any change in the effect estimate as a sensitivity analysis, to provide a more valid estimate by having analytic consistency, and to offer more generalizability in the clinical practice by including all the available data [31]. Across the meta-analysis, the statistical significance was set as a p value < 0.05.

**Grading the strength of the evidence**

We judged the overall quality of evidence for each outcome in the involved trials using the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) approach and created “Summary of findings” tables using GRADE Profiler (GRADEpro GDT) [32], following the guidance in the Cochrane Handbook for Systematic Reviews of Interventions [33]. Our GRADE judgment of certainty was achieved through consideration of these five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias.

Subgroup analysis and exploration of heterogeneity
To assess the heterogeneity, subgroup analyses were planned when feasible by having at least two studies in at least two subgroups for the primary outcome. The approach of “leave-one-out” sensitivity analysis was implemented to assess the stability of the meta-analysis outcomes [34].

RevMan 5.3 software: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014 [35] was used to perform the analysis.

Results
The initial electronic search yielded 3195 citations. After reviewing the titles and abstracts, twenty-six studies were retrieved for more thorough screening, and a total of ten RCTs met our modified inclusion criteria (Additional File 1 A), as shown in Fig. 1. In these ten studies, there was a total of 1039 participants (530 in the IV iron group and 509 in the control group). All patients were scheduled to have major surgery; two studies involved orthopedic surgery [36, 37], two involved cardiac surgery [38, 39], two involved gynecological surgery [40, 41], two involved colorectal surgery [42, 43], one involved major abdominal surgery [44], and one included a mixture of orthopedic, and cardiovascular surgery [45]. The trial’s characteristics are summarized in Table 1 and Additional File 1 E.

All trials completed the full target dose of IV iron administration preoperatively except for two trials [36, 38] where the injection was initiated preoperatively, and the rest of the dose was completed after surgery. Each trial’s iron injection regimen is detailed in Table 1 and Additional File 1 E.

The follow-up went beyond hospital discharge in four trials [37–39, 44]. The publication dates of the included trials ranged between 1999 [45] and 2017 [43].

Risk of bias assessment
Four [36, 38, 42, 43] of the ten trials were judged as having a low risk of bias across the entire set of domains,
| Study and the publication year | Country | Surgery type | Mean age (SD): intravenous iron/control or oral iron | Patients’ #: intravenous iron/control or oral iron | Anemic patients were recruited | Comparator | Intravenous iron dosage regimen | Last follow-up time |
|--------------------------------|---------|--------------|---------------------------------------------------|-------------------------------------------------|--------------------------------|-----------|-------------------------------|-------------------|
| Bernabeu-Wittel et al., 2016 [37] | Spain   | Hip fracture surgery | 84.6 ± 6.2/82.3 ± 6.9 | 103/100 | Yes | Placebo | 1000 mg of IV Ferric carboxymaltose (two 500 mg vials diluted in a bottle of 250 mL of saline after randomization and always previously to surgery. | 60 days post-hospital discharge |
| Edwards et al. 2009 [42] | UK      | Colorectal cancer resection | 67/70 (median) | 34/26 | Some patients were anemic | Placebo | 300 mg iron sucrose in 2 infusions separated at least 24 h apart, 14 days pre-surgery. | Hospital discharge |
| Froessler et al. 2016 [44] | Australia | Major abdominal surgery | 64 ± 15/68 ± 15 | 40/32 | Yes | Usual care | Ferric carboxymaltose, 15 mg/kg with maximum dose of 1000 mg between 4 and 21 days before surgery. Post-surgery, within 2 days of surgery, participants received 0.5 mg of ferric carboxymaltose per recorded 1 mL of blood loss, if blood loss was > 100 ml. | 4 weeks post-surgery. |
| Garrido-Martín et al. 2012 [38] | Spain   | Cardiac surgery | 65 ± 11/65 ± 12 | 54/52 | No | Placebo | Three doses of iron sucrose 100 mg/24 h during pre- and postoperative hospitalization. | 1 month post-discharge |
| Johansson et al. 2015 [39] | Denmark | Cardiac surgery | 65 ± 8/65 ± 11 | 30/30 | No | Placebo | A single-dose infusion of 1000 mg with a maximum single dose of 20 mg/kg. The injection was a day before surgery or same day. | 4 weeks after surgery |
| Keeler et al. 2017 [43] | UK      | Colorectal cancer resection | Median (IQR) 73.8 (67.4–78.6)/74.7 (67.9–80.8) | 55/61 | Yes | Oral iron | Ferric carboxymaltose with a maximum dose of 1000 mg per week and a maximum of 2000 mg during the trial. The first dose of injection was at least 2 weeks pre-surgery. | 2–3 months post-hospital discharge |
| Kim et al. 2009 [40] | South Korea | Gynecologic surgery for menorrhagia | 42.0 ± 7.4/42.3 ± 8.0 | 30/26 | Yes | Oral iron | A 200-mg dose of intravenous iron sucrose three times a week starting 3 weeks prior surgery until target hemoglobin of 10 g/dL was achieved. The treatment started 3 weeks pre-surgery. | Hospital discharge |
| Serrano-Trenas et al. 2011 [36] | Spain   | Hip fracture surgery in elderly patients | 83.46 ± 7.1/82.53 ± 6.4 | 99/97 | Some patients were anemic | Standard protocolized treatment | Iron sucrose 200 mg at 48-hour intervals for 3 doses, starting on the day of admission; the first dose was given pre-surgery. The following doses were administered before or after surgery, depending on the time of surgery. | 7 days post-surgery |
| Shah et al. 2016 [41] | India   | Gynecologic surgery for menorrhagia | Most of ages are between 40 and 49 years | 55/55 | Yes | Oral iron | A 100-mg dose of iron sucrose in 100 ml (2 ampoules) by slow IV infusion. Starting 4-weeks pre-surgery, the dose was repeated on alternate day basis until target hemoglobin of 10 g/dL was achieved. | Hospital discharge |
| Weisbach et al. 1999 [45] | Germany | Orthopedic or cardio-vascular surgery | 64.4 ± 14.7/64.1 ± 9.5 | 30/30 | No | Usual care | A 200-mg dose of iron sucrose, given after each donation and at the enrolment before the first donation. | Hospital discharge |
while six trials [37, 39–41, 44, 45] were assessed to have an unclear or high risk of bias in one, or a maximum of two different domains. Details of the risk of bias judgment for each study are shown in Fig. 2, and item-specific judgments for studies are presented in Additional File 1 D.

Except for only one trial [37] that did not provide detailed information on the methods used to achieve allocation concealment, all trials have proper random sequence generation and allocation concealment. Lack of blinding in this kind of study is less likely to generate bias when calculating measurable outcomes like transfusion rate, Hb and ferritin levels, or mortality. Moreover, when comparing IV iron with oral iron, blinding would be difficult due to the effect of oral iron on stool color.

**Exposure for allogeneic blood transfusion**

Overall, the proportion of transfused patients was 33% in the IV iron versus 40% in the other group. Accordingly, IV iron injection showed significantly higher efficacy, achieving a reduction of 16% in the proportion of patients requiring ABT. This pooled effect estimate was statistically significant (RR between the study groups: 0.84, 95% confidence interval [CI]: 0.71, 0.99, \( p = 0.04 \)) under the random-effects model (Fig. 3). Under the fixed-effects model, the reduction increased slightly to 17% (RR: 0.83, 95% CI: 0.70, 0.98, \( p = 0.03 \)) (Fig. 4). There was no statistical heterogeneity in ABT in either model, with a Cochran Q statistic (\( p = 0.59 \)) and a corresponding \( I^2 \) statistic of 0%. As a sensitivity analysis, after excluding one study [45] designed mainly to improve autologous blood donation pre-surgery, the reduction of ABT increased slightly to 17% (RR: 0.83, 95% CI: 0.70, 0.98, \( p = 0.02 \)) (Additional File 2 A: Figure 1).

However, a direct comparison between IV iron versus oral iron trials arms that included only three studies in the analysis was not able to find any transfusion rate difference (Fig. 5).

Given the different kinds of major surgeries using different IV iron preparations with dissimilar injection timing, subgroup analyses were conducted comparing cardiac [38, 39] versus non-cardiac studies [36, 37, 42–44], iron sucrose [36, 38, 42, 45] versus a ferric carboxymaltose IV iron preparation [37, 43, 44], and early injection (> 2 weeks pre-surgery) [43, 45] versus late injection of iron (\( \leq 2 \) weeks of surgery) [36–39, 42, 44]. All analyses showed no statistically significant subgroup effect (\( p = 0.52 \), \( p = 0.98 \), and \( p = 0.56 \)) respectively (Additional File 2 B: Figure 1-3).

Although we included ten trials, only eight studies [36–39, 42–45] reported transfusion data, so we were not able to conduct a meta-regression [30] or to explore publication bias by checking the funnel plot asymmetry [46] as this requires at least ten trials. Due to Hb measurement timing variability, we did not have ten studies contributing to the same time point analysis.

**Hemoglobin concentration change**

While the Hb levels MD of baseline-pooled estimate was comparable between groups (Additional File 2 C: Figure 1), after completion of the preoperative IV iron administration, we found a significant Hb level increase in favor of the IV iron group (MD between groups: 7.15 g/L, 95% CI: 2.26, 12.04, \( p = 0.004 \)) (Fig. 6). Similarly, a direct comparison between IV iron versus oral iron participants revealed a significant Hb level rise in favor of the IV iron group (MD between groups: 7.63 g/L, 95% CI: 1.41, 13.86, \( p = 0.02 \)) when the analysis included five studies (Fig. 7). In following this increase difference at pre-surgery, the between-group difference dropped rapidly throughout the
hospital stay, and there were no significant differences noted at the first postoperative day or hospital discharge time across groups (Additional File 2: Figure 2-3).

Interestingly, post-hospital discharge, the pooled effect [37–39, 44] showed a significant increase in the Hb difference in favor of the IV iron group (MD between groups: 6.46 g/L, 95% CI: 3.10, 9.81, \( p = 0.0002 \)) (Fig. 8).

**Ferritin levels**

While the ferritin levels MD of baseline-pooled estimate was comparable between groups (Additional File 2-D: Figure 1), administration of IV iron was capable of causing marked improvements in the depleted iron stores replenishment in favor of the IV iron group at pre-surgery, hospital discharge, and >4 weeks postoperatively, (MD between groups: 94.09 ng/mL, 95% CI: 51.57, 136.61, \( p < 0.0001 \)), (MD between groups: 547.77 ng/mL, 95% CI: 290.92, 1058.94, \( p = 0.04 \)), and (MD between groups: 347.57 ng/mL, 95% CI: 290.92, 404.21, \( p < 0.0001 \)) respectively (Additional File 2 D: Figure 2, 4 and 5). In addition, at pre-surgery time, a significant serum ferritin increase was obtained in favor of the IV iron group when it was compared directly with the oral iron group (MD between groups: 106.12 ng/mL, 95% CI: 32.46, 179.78, \( p = 0.005 \)), (Additional File 2 D: Figure 3).

**Iron-deficiency anemia blood tests**

For the rest of the IDA parameters, including reticulocyte (%) percentage, MCV, hematocrit value (%), transferrin saturation value (TSAT %), MCH, MCHC, and serum iron level, only a few trials contributed to the different analyses (Additional File 2 D: Figure 6-24). In
favor of the IV iron group, there are substantial increases in the reticulocyte percentage (at both pre-surgery time and hospital discharge time); and in the mean MCV level (at pre-surgery time). For the rest of these parameters, there was no significant change across groups after iron injection.

Adverse events
The participants tolerated IV iron injection well, and for non-serious (mild or moderate) AEs, there was no difference across groups (RR: 1.13, 95% CI: 0.78, 1.65, p = 0.52) (Additional File 2 E: Figure 1). After including a trial of zero events [38], the results remained similar [36–38, 40, 41, 43–45]. Regarding serious adverse effects (SAEs), similarly, there was no difference between groups (RR: 0.96, 95% CI: 0.44, 2.10, p = 0.92) [39, 43] (Additional File 2 E: Figure 2).

Mortality
There was no statistically significant difference between the two groups for the reported 30-day mortality (RR: 1.10, 95% CI: 0.60, 2.00, p = 0.76) [36, 37, 39, 44] (Additional File 2 E: Figure 3). Findings were alike after including a trial of zero events [39]. At 2 months post-hospital discharge, comparable death results (RR: 1.18, 95% CI: 0.63, 2.19, p = 0.6) were also obtained [37, 43] (Additional File 2 E: Figure 4).

Infection
Five trials [36–38, 43, 44] reported data for postoperative infection. One of these five studies [38] reported a similar infection rate between the trial arms but did not provide numbers. Another study [36] reported the total infection rate across the study (14.8%) but did not provide arm-specific numbers of infections. A third study [43] reported no difference in infection rate (p = 0.091) or grade of its severity (p = 0.083) between the trial arms but did not provide numbers. The other two studies [37, 44] showed similar infection incidence between groups (RR: 0.64, 95% CI: 0.30, 1.40, p = 0.27) (Additional File 2 E: Figure 5).

### Table 1

| Study or Subgroup | Intravenous iron | Oral iron | Risk Ratio | Risk Ratio |
|-------------------|------------------|-----------|------------|------------|
|                   | Events | Total | Events | Total | M-H, Random, 95% CI | M-H, Random, 95% CI |
| Carvillo-Martín 2012 | 20 | 54 | 27 | 53 | 0.73 [0.47, 1.13] | |
| Keeler 2017 | 10 | 55 | 14 | 61 | 0.79 [0.38, 1.64] | |
| Weistch 1999 | 6 | 30 | 2 | 30 | 3.00 [0.66, 13.69] | |
| Subtotal (95% CI) | 139 | 144 | 100.0% | 0.88 [0.51, 1.51] | |

### Table 2

| Study or Subgroup | Intravenous iron | Placebo/standard of care | Mean Difference | Weight |
|-------------------|------------------|--------------------------|-----------------|--------|
| Edwards 2009 | 134 | 27 | 136 | 26 | 28 | 7.9% | -2.0% [15.50, 11.50] |
| Fronesta 2016 | 115 | 13 | 107 | 17 | 32 | 13.9% | 8.00 [0.86, 15.14] |
| Carvillo-Martín 2012 | 127 | 16 | 128 | 13 | 52 | 13.8% | -1.00 [4.54, 4.54] |
| Keeler 2017 | 119 | 55 | 110 | 16 | 61 | 15.7% | 9.00 [3.36, 14.64] |
| Kim 2009 | 105 | 14 | 86 | 14 | 26 | 13.7% | 19.00 [11.65, 26.35] |
| Shah 2016 | 107 | 7 | 95 | 7 | 55 | 18.7% | 11.00 [8.38, 13.62] |
| Westch 1999 | 127 | 10 | 125 | 16 | 30 | 14.4% | 2.00 [4.75, 8.75] |
| Total (95% CI) | 298 | 282 | 100.0% | 7.15 [2.26, 12.04] | |

### Figure 5

Forest plot comparison shows the pooled direct comparison effect of intravenous iron therapy versus oral iron groups on the proportion of the transfused patients as a subgroup analysis (random effects model).

### Figure 6

Forest plot comparison shows the pooled comparison effect of intravenous iron therapy versus placebo/standard of care groups on the change of hemoglobin level (g/L) at the post-treatment (pre-surgery) time (random effects model).
Hospital length of stay

Five trials [36, 37, 42–44] reported data about hospital LOS. However, none of the individual studies showed a statistical difference across the trial arms, and we were not able to pool them as four trials [37, 42–44] provided the LOS as median days.

Quality of life

Health-related quality of life data were provided in only two trials [37, 44] that used two different tests, which makes quantitative analysis not feasible. The first trial [37] used the Short Form 36 Version 2 for acute patients (SF-36v2) [47], at 60 days post-hospital discharge reassessment; it revealed statistically non-significant and clinically unimportant changes. Similar findings were observed in the second trial [44] that used the short form health survey (SF36) [48] at 4 weeks post-surgery reassessment.

Discussion

The core finding of this meta-analysis, based on moderate-quality evidence, was a 16% reduction in the ABT for the participants who received the iron injection (Additional File 3). In addition, pre-surgery Hb and ferritin levels increase accompanied by ABT reduction, with no change in postoperative infections, AE, or mortality rate.

For transfusion rate reduction, the minimal clinically significant difference (MCID) cutoff has not been established yet. However, the largest currently ongoing trial investigating iron injection to treat preoperative anemia in major surgery used a risk reduction of 12% in the transfusion rate to calculate the sample size [49]. Therefore, in this meta-analysis, it would seem that after receiving IV iron, a reduction of 16% in the proportion of patients requiring ABT might be considered clinically important and sufficient to change patient management. This transfusion reduction in our study is in accordance with previous large meta-analysis of both surgical and nonsurgical RCTs [50], a recent surgical meta-analysis [51], several observational studies [52–61], and a pooled analysis of observational data from 2547 patients [62]. This finding is of great benefit for all patients, including Jehovah’s Witness (JW) patients, where ABT is forbidden, patients who will be potentially organ recipients, patients for whom transfusions are medically contraindicated, and those who are living in countries with restricted resources.

In the current meta-analysis, we included trials from different surgical specialties that allow for extended external validity; however, these findings may not be generalizable to patient populations other than those undergoing elective surgery. In particular, the findings from this meta-analysis conflict with a recent trial in critical care patients [63], and a meta-analysis in pregnancy [20]. In these two studies, although the Hb levels were significantly higher after IV iron therapy, there were no significant differences in blood transfusion

![Fig. 7](image_url)

_Hospital length of stay_ Five trials [36, 37, 42–44] reported data about hospital LOS. However, none of the individual studies showed a statistical difference across the trial arms, and we were not able to pool them as four trials [37, 42–44] provided the LOS as median days.

| Study or Subgroup         | Intravenous iron Mean | Intravenous iron SD | Oral Iron Mean | Oral Iron SD | Total Mean | Total SD | Total Weight | IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|---------------------------|------------------------|---------------------|----------------|-------------|------------|----------|--------------|---------------------|----------------------------------|
| Gamido-Martin 2012        | 127                    | 16                  | 128            | 17          | 53         | 19.1%    | 1.00 [−1.26, 7.26]|                                   |
| Kweiler 2017              | 119                    | 15                  | 110            | 16          | 61         | 19.8%    | 9.00 [3.35, 14.64]|                                   |
| Kim 2009                  | 105                    | 14                  | 86             | 26          | 36         | 17.8%    | 19.00 [11.65, 26.35]|                                   |
| Shah 2016                 | 107                    | 7                   | 96             | 7           | 55         | 22.7%    | 11.00 [8.38, 13.62]|                                   |
| Westbach 1999             | 127                    | 10                  | 128            | 9           | 30         | 20.7%    | −1.00 [−5.81, 3.81]   |                                   |
| Total (95% CI)            | 224                    | 100.0%              | 225            |             | 7.63 [1.41, 13.86] |                                   |

Heterogeneity: Tau² = 42.75, Chi² = 31.84, df = 4 (P < 0.0001); I² = 87%

Test for overall effect: Z = 2.40 (P = 0.02)

_Fig. 7_ Forest plot comparison shows the pooled comparison effect of intravenous iron therapy versus oral iron groups on the change of hemoglobin level (g/L) at the post-treatment (pre-surgery) time (random effects model)

![Fig. 8](image_url)

_Discussion_ The core finding of this meta-analysis, based on moderate-quality evidence, was a 16% reduction in the ABT for the participants who received the iron injection (Additional File 3). In addition, pre-surgery Hb and ferritin levels increase accompanied by ABT reduction, with no change in postoperative infections, AE, or mortality rate.

For transfusion rate reduction, the minimal clinically significant difference (MCID) cutoff has not been established yet. However, the largest currently ongoing trial investigating iron injection to treat preoperative anemia in major surgery used a risk reduction of 12% in the transfusion rate to calculate the sample size [49]. Therefore, in this meta-analysis, it would seem that after receiving IV iron, a reduction of 16% in the proportion of patients requiring ABT might be considered clinically important and sufficient to change patient management. This transfusion reduction in our study is in accordance with previous large meta-analysis of both surgical and nonsurgical RCTs [50], a recent surgical meta-analysis [51], several observational studies [52–61], and a pooled analysis of observational data from 2547 patients [62]. This finding is of great benefit for all patients, including Jehovah’s Witness (JW) patients, where ABT is forbidden, patients who will be potentially organ recipients, patients for whom transfusions are medically contraindicated, and those who are living in countries with restricted resources.

In the current meta-analysis, we included trials from different surgical specialties that allow for extended external validity; however, these findings may not be generalizable to patient populations other than those undergoing elective surgery. In particular, the findings from this meta-analysis conflict with a recent trial in critical care patients [63], and a meta-analysis in pregnancy [20]. In these two studies, although the Hb levels were significantly higher after IV iron therapy, there were no significant differences in blood transfusion

![Fig. 8](image_url)

_Hospital length of stay_ Five trials [36, 37, 42–44] reported data about hospital LOS. However, none of the individual studies showed a statistical difference across the trial arms, and we were not able to pool them as four trials [37, 42–44] provided the LOS as median days.

| Study or Subgroup         | Intravenous iron Mean | Intravenous iron SD | Placebo/standard of care Mean | Placebo/standard of care SD | Total Mean | Total SD | Total Weight | IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|---------------------------|------------------------|---------------------|-------------------------------|---------------------------|------------|----------|--------------|---------------------|----------------------------------|
| Bonnello-Witt 2016        | 124                    | 15                  | 103                           | 19                       | 110        | 100      | 40.7%        | 5.00 [3.38, 8.61]       |                                   |
| Freseste 2016             | 122                    | 14                  | 112                           | 12                       | 32         | 24.6%    | 11.00 [5.42, 16.58] |                                   |
| Gamido-Martin 2012        | 127                    | 15                  | 123                           | 11                       | 52         | 30.0%    | 4.00 [−0.78, 8.78]  |                                   |
| Johanssen 2015            | 126                    | 16                  | 115                           | 39                       | 30         | 4.6%     | 11.00 [4.08, 18.08] |                                   |
| Total (95% CI)            | 227                    | 100.0%              | 214                           |                           | 6.46 [3.10, 9.81] |                                   |

Heterogeneity: Tau² = 3.80, Chi² = 4.47, df = 3 (P = 0.22); I² = 33%

Test for overall effect: Z = 3.77 (P = 0.0002)

_Fig. 8_ Forest plot comparison shows the pooled comparison effect of intravenous iron therapy versus placebo/standard of care groups on the change of hemoglobin level (g/L) as follow-up > 4 weeks postoperatively (random effects model)
was capable of augmenting Hb level. This increase was with a very recent surgical meta-analysis where IV iron Moreover, our Hb increase pattern over time is in line [53, 56, 69]
crease in our meta-analysis is consistent with two feasi-
dose of IV iron injection. Overall, this detected Hb in-
waves indicating the importance of the early and second
positive effect in the pooled estimate in both Hb rise
nations, two meta-analyses did not show evidence of trans-
fusion reduction in non-elective surgery [65], or when
iron injected postoperatively [66], indicating the impor-
tance of injecting iron pre-surgery by sufficient time.
In our meta-analysis, although there was no statistical
heterogeneity as \( I^2 \) was zero% in both random and fixed-
effects models, there was a discrepancy in ABT reduc-
tion rate between the two models that could ensue due
to type I error indicating a shortage of power to identify
trials’ heterogeneity. However, the clinical heterogeneity
of trials was explored using sensitivity and subgroup
analyses. Our subgroup analyses were conducted by
comparing cardiac [38, 39] versus non-cardiac surgeries
[36, 37, 42–44], iron sucrose [36, 38, 42, 45] versus car-
boxymaltose IV iron preparation [37, 43, 44], and early
[43, 45] versus delayed iron injection [36–39, 42, 44].
Interestingly, none of these analyses showed any statisti-
cally significant subgroup influence to modify the effect
of IV iron. We think that this analysis may not be able
to identify subgroup differences due to a smaller number
of studies/participants and/or uneven covariate distribu-
tion, producing uncertainty in the results.
Interestingly, in our meta-analysis, the Hb increase
tendency had a bi-phasic pattern composed of two
waves. This pattern rise might be related to the IV iron
timing variability of administration either early (2–5
weeks before the operation) in some trials [40–43, 45] or
late (around surgery time) in other trials [36–39, 44].
The disappearance of the first wave might be related to the
attenuation/termination of the IV iron effect and/or the
substantial perioperative acute blood loss. One study
[44] that administered about a thousand grams of the IV
iron 4–21 days pre-surgery in addition to extra doses of
IV iron increments postoperatively contributed to a
positive effect in the pooled estimate in both Hb rise
waves indicating the importance of the early and second
dose of IV iron injection. Overall, this detected Hb in-
crease in our meta-analysis is consistent with two feasi-
bility studies [67, 68], and several observational studies
[53, 56, 69–71], where IV iron was given pre-surgery. More-
over, our Hb increase pattern over time is in line with a very recent surgical meta-analysis where IV iron
was capable of augmenting Hb level. This increase was
higher when it was measured at 2 to 4 weeks of follow-
up (MD = 5.69 g/L, 95% CI: 2.11–9.27), but not when
calculated earlier [66] supporting a previous surgical trial
that showed IV iron achieved an increase at 4 weeks
after IV iron administration [72]. These findings, and
ours, suggest that iron injection should be initiated
about 4 weeks pre-surgery and continued till surgery
using a second dose with at least a week interval from
the first injection in order to achieve a long and sus-
tained effect to stimulate the erythropoiesis on time to
protect against ABT through moving the peak effect to
be at the perioperative time [53, 70].

The other observation was that the Hb rise did not
happen when the trial’s participants received a total
dose of \( \leq 600 \) mg of IV iron [36, 38, 42], only the rise
occurred significantly when a higher dose of iron was
injected [37, 39–41, 43, 44], demonstrating a pattern
of positive dose-response relationship supporting the
recent consensus recommendation to give a dose be-
tween 1000 and 1500 mg of IV iron in one or two di-
vided doses [73]. As our meta-analysis is for the
RCTs, it would be plausible to infer a causal relation-
ship between iron injection and Hb increase tendency.
Accordingly, we think that patients who receive a total
dose of <1000 mg of iron or who are injected
only around the time of surgery would not respond
as well as those receive larger dose administered at
least 2 weeks pre-surgery.

In our meta-analysis, although the Hb rise by 7.15 g/L
is statistically significant, this rise is still considered
below the defined clinical meaningful hemoglobin-
concentration increase (\( \geq 1 \) g/dL) [74]. Interestingly, this
modest Hb increase was associated with meaningful
transfusion reduction.

Another observation is that the ferritin rise peak was
at hospital discharge time preceding the second wave of
the Hb rise as iron replenishment is a process that hap-
ens before Hb formation. These data support other in-
vestigators’ findings [53, 70]. Another finding we found
was the reticulocyte percentage/count increase post-
treatment and during the hospital stay, demonstrating a
continued recent bone marrow activity to prepare for
the second wave appearance.

We did not find a significant difference in AEs occur-
rence between the groups, although six trials [37, 39–41,
43, 44] injected doses of \( \geq 1000 \) to 2000 mg of iron in
one trial [43]. This finding is in harmony with nonsurgi-
cal trials using up to 2000 mg [75] or 2500 mg of IV iron
[76], two surgical meta-analyses [65, 77], a meta-analysis
in IDA [78], and surgical observational studies [56, 79].
The chief AEs related to IV iron administration in our
study were erythema with pain/itching at the injection
site, phlebitis, discomfort, fever, and dizziness. Nausea,
vomiting, constipation, and diarrhea were more frequent
in those participants who received oral iron.

Given the relatively small sample size of each trial and
the relative rarity of severe side effects as the anaphylactic
shock reactions, there is a need for a large-scale phase III clinical trial or a large observational report to study the incidence of the AEs of IV iron. However, according to the United States Death Certificate Registry, only three mortalities were coded as ‘AEs in therapeutic use of iron preparation’ over the period between 1979 and 2006 [80], and the actual anaphylaxis was very rare [16].

In this meta-analysis, the iron injection did not change our study mortality, LOS, or postoperative infection rates, consistent with a recent surgical meta-analysis [65].

Strengths of the study
This meta-analysis protocol was registered and published. We followed the recommendations of the Cochrane collaboration and PRISMA statement. Our search was comprehensive without having any time, language, or IV iron preparation restrictions. It has broad external generalizability for many surgical subspecialties. As it included only RCTs, it provides high-quality evidence in practice. All analyses were performed using both fixed-effect and random-effect models. When in between-study heterogeneity exists, both techniques may be biased, but random-effects models will be more conservative.

Limitations of the study
The first limitation is some of the included studies recruited non-anemic patients, which would bias their findings toward the null. Second, the current study findings may not be generalizable to younger patients undergoing major surgery as eight of the ten trials had a mean/median age above 64 years old. Only two gynecological studies investigated younger female patients experiencing menorrhagia; a condition that usually exists at a younger age. A third potential limitation of this meta-analysis is the relatively smaller sample size of most of the trials that necessitate careful interpretation of the reported side effects of IV iron since more extensive studies are needed to identify side effects. The fourth limitation is that we estimated/imputed SD for trials when these were not published. This could be a source of bias, although the alternative would have been to exclude those trials. Doing so would have resulted in a smaller sample size of this meta-analysis and would have introduced another kind of bias that would have made the interpretation of findings difficult.

Conclusion
Based on moderate-quality evidence, our results are in support of preoperative intravenous iron administration to reduce the likelihood of allogeneic blood transfusion and to provide a modest increase in hemoglobin concentration in major surgery settings. This evidence came from eight trials for the transfusion proportion and seven trials for the hemoglobin change.

Similarly, with moderate-quality evidence, a greater increase in serum ferritin pre-surgery was found post iron injection.

Low-quality evidence suggests that surgical patients tolerate the non-serious adverse events of intravenous iron supplementation. However, with high-quality evidence, no evidence suggests that iron injection decreases mortality.

However, our findings did not show the superiority of parenteral iron therapy over oral iron on the proportion reduction of the transfused patients as a subgroup analysis. Accordingly, new trials could be made to have a robust evidence-body, and we recommend a robust clinical trial testing the hypothesis that an optimally timed injected iron in a large dose (1500–2000 mg) is safe to counteract acute perioperative blood loss.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13643-021-01579-8.

Abbreviations
ABT: Allogeneic blood transfusion; IDA: Iron-deficiency anemia; IV: Intravenous; Hb: Hemoglobin; RCT: Randomized controlled trial; AEs: Adverse events; PROSPERO: Prospective Register of Systematic Reviews; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses; CPCI: Conference Proceedings Citation Index; RR: Risk ratios; CI: Confidence intervals; MD: Mean difference; SD: Standard deviation; MCV: Mean corpuscular volume; TSAT%: Transferrin saturation value; MCH: Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin concentration; SAEs: Serious adverse effects; LOS: Hospital length of stay; HRQoL: Health-related quality of life; SF-36v2: Short form 36 version 2 for acute patients; SF36: Short form health survey; MCID: The minimal clinically important difference; JW: Jehovah Witness

Acknowledgements
Dr. Bagshaw is supported by a Canada Research Chair in Critical Care Nephrology. The authors thank Mrs. Trish Chatterley, a Collections Manager at John W. Scott Health Sciences Library at the University of Alberta, for her support in devising our search strategy. Also, we thank Ms. Laila Elhenawy, a student in the Psychology Department at the University of Alberta, for her help conducting the evidence table from the included trials as double checkers for the numbers to eliminate the human being errors in the meta-analysis.

Authors’ contributions
All data in the current study were collected and synthesized by Dr. Elhenawy, with Dr. Meyer serving as an independent second reviewer. Dr. Elhenawy conducted all statistical analyses and wrote the entire manuscript. Dr. Meyer, Dr. Bagshaw, and Dr. Carroll guided during the progress of the study. All authors read and approved the final meta-analysis.
Authors’ information

Abdelsalam M. Elhenawy, MD, MSc (Surg), MSc (Epi), Ph.D (Surg)—has been involved with cardiac valves, heart/lung transplantation, mechanical circulatory support, trans-apical cardiac valve replacement, and ischemic mitral regurgitation surgery, research and publications.

Steven R. Meyer, MD, Ph.D.—has been involved with lung and heart transplantation research, mechanical circulatory support, trans-apical cardiac valve replacement, blood conservation strategies, and evidence-based medicine.

Sean M. Bagshaw, MD, MSc—involved in prospective clinical trials, systematic reviews, meta-analysis, and production of clinical guidelines in critical care nephrology.

Roderick G MacArthur, MD, MSc—has been involved in complex aortic arch, lung and heart transplantation, mechanical circulatory support research, and surgery.

Linda Carroll, PhD—has been involved with observational studies, systematic reviews and meta-analyses, methods development, and clinical guideline development in the areas of neck pain, whiplash, traumatic brain injury, catastrophic traffic injuries, depression, and multiple sclerosis.

Availability of data and materials

Study protocol: available at www.crd.york.ac.uk/prospero (PROSPERO: CRD42018098604).

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Division of Cardiac Surgery, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
2Division of Cardiothoracic Surgery, Al Azhar University, Cairo, Egypt.
3Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
4School of Public Health, University of Alberta, Edmonton, Alberta, Canada.

Received: 4 May 2020 Accepted: 2 January 2021

Published online: 23 January 2021

References

1. Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pease RM. Meta-analysis of the association between preoperative anemia and mortality after surgery. Br J Surg. 2015;102(11):1314–24.

2. Boening A, Boedeker RH, Scheibelhut C, Rietzschel J, Roth P, Schonburg M. Anemia before coronary artery bypass surgery as additional risk factor increases the perioperative risk. Ann Thorac Surg. 2011;92(3):805–10.

3. Miceli A, Romeo F, Glauber M, de Siena PM, Caputo M, Angelini GD. Preoperative anemia increases mortality and postoperative morbidity after cardiac surgery. J Cardiothorac Surg. 2014;9:137 8090-9-137.

4. Yanes Vidal GJ. Anemia in candidates for heart surgery. Rev Esp Anestesiol Reanim. 2015;62(Suppl 1):69–85.

5. Mueller MM, Van Remoortel H, Meybohm P, Arakno K, Aubron C, Burger R, Carson JL, Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia. North American clinical trial. Am J Kidney Dis. 2001;37(2):300–7.

6. DeLoughery TG. Safety of oral and intravenous iron, Acta Haematol. 2019;142(1):8–12.

7. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: a systematic review and meta-analysis. J Perinatol. 2019;39(4):366–76.

8. Trentino KM, Leahy MF, Sanfilippo FM, Farmer SL, Hofmann A, Mace H, Murray K. Associations of nadir haemoglobin level and red blood cell transfusion with mortality and length of stay in surgical specialties: a retrospective cohort study. Anaesthesia. 2019;74(6):726–34.

9. Paone G, Brewer R, Theurer PT, Bell GF, Cogan CM, Prager RL, Michigan Society of Thoracic and Cardiovascular Surgeons. Preoperative predicted risk does not fully explain the association between red blood cell transfusion and mortality in coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2012;143(1):178–85.

10. Hopewell S, Omar O, Hyde C, Yu LM, Doree C, Murphy MF. A systematic review of the effect of red blood cell transfusion on mortality: Evidence from large-scale observational studies published between 2006 and 2010. BMJ Open. 2013;3(5):e002154.

11. Leichtste SW, Mouawad NJ, Lampman R, Singh A, Cleary RK. Does preoperative anemia adversely affect colon and rectal surgery outcomes? J Am Coll Surg. 2011;212(2):187–94.

12. Musallam K, Tamir H, Richards T, Spaeth DR, Rosendaal FR, Habbal A, Kheissi M, Dahnalhe F, Khavandi K, Sier PM, Soxiewd A, Hoballah JJ, Taher AT, Jamali FR. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011;378(9800):1396–407.

13. Lebun F, Klastersky J, Levaqc D, Wissam Y, Paemans M. Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies. Support Care Cancer. 2017;25(7):2313–9.

14. Bhati SB, Jaju PB. Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy: A randomized controlled trial. BMJ Pregnancy Childbirth. 2017;1(1):137 017-1313-9.

15. Lewkowicz AK, Gupta A, Simon L, Sabol BA, Stoll C, Cooke E, Rampersad RA, Tuuli MG. Intravenous compared with oral iron for the treatment of iron-deficiency anemia in pregnancy: a systematic review and meta-analysis. Am J Perinatol. 2019;36(4):366–76.

16. Aksan A, Isik H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1303–13.

17. Elhenawy AM, Meyer SR, Bagshaw SM, MacArthur RG, Carroll LJ. Role of preoperative intravenous iron therapy to correct anaemia before major surgery: study protocol for systematic review and meta-analysis. Syst Rev. 2015;4:29 015-0016-4.

18. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Syst Rev. 2015(8):336–41.

19. Padmanabhan H, Siau K, Nevill AM, Morgan I, Cotton J, Ng A, Brookes MJ, Luckraz H. Intravenous iron does not effectively correct preoperative anaemia in cardiac surgery: a pilot randomized controlled trial. Interact Cardiovasc Thorac Surg. 2019;28(3):447–54.

20. Richards T, Bailykay RR, Clevenger B, Butcher A, Abeyriri S, Chau M, MacDougall IC, Murphy G, Swinson R, Collier T, Van Dyck L, Browne J, Bradbury A, Dodd M, Evans R, Brealey D, Anker SD, Klein A. Preoperative
intravenous iron to treat anaemia before major abdominal surgery (PREVEN T1); a randomised, double-blind, controlled trial. Lancet. 2020;396:1353–61.

27. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. Cochrane Bias Methods Group, Cochrane Methodological Assessment. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

28. Dollma D, Elliott P, Suh J, Cutler J. Variance imputation for continuous variables with missing data: an example. J Clin Epidemiol. 1992;45(7):769–73.

29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

30. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 (updated March 2011). Version 5.1.0 ed. Higgins JPT, editor. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org. [Internet. Accessed 13 Sept 2013].

31. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007;7:5.

32. GRADEpro GDT. McMaster University (developed by Evidence Prime). GRADEpro GDT Version accessed 12 Dec 2018. Hamilton (ON): McMaster University (developed by Evidence Prime); 2015.

33. Schünemann H, Oxman A, Vist G, Higgins J, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Cochrane handbook for systematic reviews of interventions Version 5.1.0 (updated March 2011). Edited by Higgins J, Green S. The Cochrane Collaboration; 2011. Available from: http://handbook.cochrane.org/chapter_12/12_interpreting_results_and_drawing_conclusions.htm. [Internet. Accessed 13 Sept 2013].

34. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stat. Tech Bull. 1999:8:15–7.

35. The Nordic Cochrane Centre. The Cochrane Collaboration: RevMan 5.3 beta | Informatics & Knowledge Management Department. 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.

36. Serrano-Trejas NA, Ugalde PF, Cabello LM, Choffles LC, Lazoro PS, Benezic PE. Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. Transfusion. 2011;51(1):97–104.

37. Bernabeu-Wittel M, Romero M, Ollero-Baturone M, Aparicio R, Murcia-Zaragoza J, Rincon-Gomez M, Monte-Secades R, Melero-Bascones M, Rosso CM, Ruiz-Cantero A, PAHFRAC-01 Investigators. Ferric carboxymaltose with or without erythropoietin in anaemic patients with hip fracture: a randomized clinical trial. Transfusion. 2016;56(9):2199–211.

38. GarridoMartín P, NasserMansur ML, de la Llanaducros R, VigarosAller TM, Rodriguez Fortuzne PM, AvalsPinto R, JimenezSosa A, MartinezSanz R. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial. Interact Cardiovasc Thoracic Surg. 2012;15(6):1013–8.

39. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (monfer(R)) reduces postoperative anaemia in preoperatively anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTect trial). Vox Sang. 2015;109(2):57–66.

40. Kim YH, Chung HH, Kang SB, Kim SC, Kim YT. Safety and usefulness of intravenous iron sucrose in the management of anaemic women with menorrhagia. Natl J Commun Med. 2016;7(1):60–3.

41. Shah J, Vachhani A, Mehta M, Kongnathi S. Safety and effectiveness of intravenous iron in anaemic patients with colorectal cancer. Br J Surg. 2017;104(3):214–21.

42. Froselser B, PP, WI, HN, SR, ME. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg. 2016;264(1):41–6.

43. Weisbach V, Skoda P, Rippel R, Lauer G, Glaser A, Zingsem J, Zimmermann R, Eckstein R. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion. 1999;39(5):465–72.

44. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.

45. Ware JE, Kosinski M, Gandek B. New England Medical Center Hospital. SF-36 health survey: manual and interpretation guide. Boston, Mass: The Health Institute, New England Medical Center Hospital; 2002.

46. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care. 1992;30(6):473–83.

47. Richards T, Clevenger B, Reardon J, Collier T, Klein AA, Anker SD, Kelly JD. PREVENTT: perioperative intravenous iron treatment to treat anaemia in major surgery: study protocol for a randomised controlled trial. Trials. 2015;16:254:015–07748.

48. Litton E, Xiao J, HO KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4922.

49. Schack A, Berikofs AA, Ekelof S, Gogenur I, Burchath J. The effect of perioperative iron therapy in acute major non-cardiac surgery on allogeneic blood transfusion and postoperative haemoglobin levels: a systematic review and meta-analysis. World J Surg. 2019;43(7):1677–91.

50. Quin N, Meland E, McGinn S, Anderson JH. Correction of iron-deficiency anaemia in colorectal surgery reduces perioperative transfusion rates: a before and after study. Int J Surg. 2017;38:1–8.

51. Calleja JL, Delgado S, del Val A, Hervas A, Larraona JL, Teras A, Cucala M, Mearin F, Colon Cancer Study Group. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis. 2016;31(3):543–51.

52. Lasa-Morales M, Gomez R, Pontes G, Diaz EC, Munoz M. Intravenous versus oral iron for treating iron deficiency anaemia in colorectal cancer patients: a single-centre, observational cohort study. Transfusion Medicine. 2016;26Suppl(1):S3.

53. Blanco Rubio N, Llorens Ezguerrur S, Seral Garcia B, Burillo Fuertes P, Ranera Garcia M, Albareda Albareda J. Preoperative intravenous iron as a strategy for blood saving in surgery for hip fracture. Med Clin (Bac). 2013;141(9):371–5.

54. Lasa-Morales M, Jerico C, Gomez-Ramirez S, Castellvi J, Viso L, Roig-Martinez J, Pontes C, Munoz M. Preoperative management of colorectal cancer-induced iron deficiency anaemia in clinical practice: data from a large observational cohort. Transfusion. 2017;57(12):3040–8.

55. Diaz Espallardo C, Lasa Morales MJ, Collies Calvet C, Mora Lopez L, Roig Martinez J, Lasa Marin MT. The multidisciplinary approach is useful for optimising preoperative haemoglobin in colorectal cancer surgery. Cir Esp. 2011;89(6):392–9.

56. Bibé E, García-Erce JA, Diez-Lobo AI, Munoz M, Anaemia Working Group Espana. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth. 2011;107(3):477–8.

57. Diez-Lobo A, Fisac-Martín M, Bermejo-Ayar J, Munoz M. Preoperative intravenous iron administration corrects anaemia and reduces transfusion requirement in women undergoing abdominal hysterectomy. Transfus Altern Med. 2007;9(2):114–9.

58. Cuenca J, García-Erce JA, Martínez AA, Solano VM, Molina J, Munoz M. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg. 2005;125(5):342–7.

59. Cuenca J, García-Erce JA, Munoz M, Izuel M, Martinez AA, Herrera A. Patients with pertochohanatic hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. Transfusion. 2004;44(10):1447–52.

60. Munoz M, Gomez-Ramirez S, Cuenca J, Garcia-Erce JA, Ileglesias-Aparicio D, Haman-Alcober S, Ariza D, Naveira E. Very-short-term perioperative iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion. 2014;54(2):289–99.
IRONMAN Investigators, Litton E, Baker S, Erber WN, Farmer S, Ferrier J, French C, Gummer J, Hawkins D, Higgins A, Hofmann A, De Keulenaer B, McMorrow J, Olynyk J, Richards T, Towler S, Trengove R, Webb S, Australian and New Zealand Intensive Care Society Clinical Trials Group. Intravenous iron or placebo for anaemia in intensive care: The IRONMAN multicentre randomized blinded trial: a randomized trial of IV iron in critical illness. Intensive Care Med. 2016;42(11):1715–22.

Shah A, Roy NB, McKechnie S, Doree C, Fisher SA, Stanworth SJ. Iron supplementation to treat anaemia in adult critical care patients: a systematic review and meta-analysis. Crit Care. 2016;20(1):306.

Shah A, Palmer A, Fisher SA, Rahman SM, Brunskill S, Doree C, Reid J, Sugavanam A, Stanworth SJ. What is the effect of perioperative intravenous iron therapy in patients undergoing non-elective surgery? A systematic review with meta-analysis and trial sequential analysis. Perioper Med (Lond). 2018;7:30. 018-0109-4. eCollection 2018.

Perelman I, Winter H, Sikora L, Martel G, Saidenberg E, Fergusson D. The efficacy of postoperative iron therapy in improving clinical and patient-centered outcomes following surgery: a systematic review and meta-analysis. Transfus Med Rev. 2018;32(2):89–101.

Simpson J, Ng S, Brooks M, Acheson A. Single dose preoperative administration of intravenous iron corrects iron deficiency anaemia in colorectal cancer. J Blood Disord Transfus. 2010;1(1):1000101. https://doi.org/10.4172/2155-9864.

Keeler BD, Simpson JA, Ng S, Tselepis C, Iqbal T, Iqbal B, Brookes MJ, Acheson AG. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis. 2014;16(10):794–800.

Munoz M, Garcia-Erce JA, Diez-Lobo A, Campos A, Sebastianes G, Bistr E, Anaemia Working Group Espana (AWGE). Usefulness of the administration of intravenous iron sucrose for the correction of preoperative anaemia in major surgery patients. Med Clin (Barc). 2009;132(8):303–6.

Theusinger OM, Leyvraz PF, Schanz U, Seifert B, Spahn DR. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: a prospective study. Anesthesiology. 2007;107(6):923–7.

Wilson MJ, Dekker JW, Buns E, Borstlap W, Jeekel J, Zwanginga JJ, Schipperus M. Short-term effect of preoperative intravenous iron therapy in colorectal cancer patients with anaemia: results of a cohort study. Transfusion. 2018;58(3):795–803.

Khalafallah AA, Yen C, Al-Badi R, Robinson E, Kirkby BE, Ingram E, Gray Z, Kheli V, Robertson IK, Kirkby BP. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol. 2016;3(9):e415–25.

Munoz M, Acheson AG, Auerbach M, Besser M, Habler O, Kehlet H, Lihrbruno GM, Lasocki S, Meybohm P, Rao Baikady R, Richards T, Shander A, So-Osman C, Spahn DR, Klein AA. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72(2):233–47.

Mouysset JL, Freier B, van den Bosch J, Levaché CB, Bols A, Tessen HW, Belton L, Bohac GC, Terwey JH, Tonini G. Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anaemia: the eAQUA study. Cancer Manag Res. 2016;8:1–10.

Evstafiev R, Manteau P, Iqbal T, Khalil II, Stein J, Borkemeyer B, Chopey IV, Gutzwiller FS, Rispe L, Gesche C, FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846–53 e1–2.

Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Pt 1):267–78.

Shin HW, Park JJ, Kim HU, You HS, Choi SU, Lee MJ. Efficacy of perioperative intravenous iron therapy for transfusion in orthopedic surgery: a systematic review and meta-analysis. PLoS One. 2019;14(5):e0215427.

Avni T, Beiber A, Grossman A, Green H, Leibovici L, Gafner-Gulri A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12–23.